Combined use of orgaran and reopro during coronary angioplasty in patients unable to receive heparin

Catheterization and Cardiovascular Interventions

Volumn 46, Issue 3, 1999, Pages 352-355

  Cantor, Warren J ^a   Leblanc, Kori ^a   Garvey, Bernadette ^a   Watson, K Randal ^a   Rasymas, Al ^a   Strauss, Bradley H ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b HEART AND STROKE FOUNDATION OF CANADA   (Canada)

Author keywords

Anticoagulant; Heparin; PTCA

Indexed keywords

ABCIXIMAB; BLOOD CLOTTING FACTOR 10A INHIBITOR; DANAPAROID; HEPARIN;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CASE REPORT; FEMALE; HEART INFARCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY; URTICARIA;

EID: 0033011461     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/(sici)1522-726x(199903)46:3<352::aid-ccd21>3.0.co;2-7     Document Type: Article

References (21)

1. Popma JJ, Coller BS, Ohman EM, Bittl JA, Weitz J, Kuntz RE, Leon MB. Antithrombotic therapy in patients undergoing coronary angioplasty. Chest 1998;108:486S-501S.
2. Becker PS, Miller VT. Heparin-induced thrombocytopenia. Stroke 1989;20:1449-1459.
3. Brieger DB, Mak KH, Kottke-Marchant K, Topol EJ. Heparin-induced thrombocytopenia. J Am Coll Cardiol 1998;31:1449-1459.
4. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemostas 1993;70:554-561.
5. Magnani HN, Beijering RJR, Ten Cate JW, Chong BH. Orgaran anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia. In: Pifarré R, editor. New anticoagulants for the cardiovascular patient. Philadelphia: Hanley and Belfus; 1997. p 487-500.
6. Ortel TL, Gockerman JP, Califf RM, McCann RL, O'Connor CM, Metler DM, Greenberg CS. Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis. Thromb Haemostas 1992;67:292-296.
7. Wilhelm MJ, Schmid C, Kececioglu D, Möllhoff T, Ostermann H, Scheid HH. Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia using Org 10172. Ann Thorac Surg 1996;61:920-924.
8. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein iib/iiia receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
9. The EPILOG Investigators. Platelet glycoprotein iib/iiia receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
10. The CAPTURE investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention inrefractory unstable angina: the CAPTURE Study. Lancet 1997;349:1429-1435.
11. Lewis BE, Iaffaldano R, McKiernan TL, Rao L, Donkin J, Wallenga JM. Report of successful use of argatroban as an alternative anticoagulant during coronary stent implantation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome. Catheter Cardiovasc Diagn 1996;38:206-209.
12. Moore JA, Burket MW, Puri S, Temesy-Armos P, Lachant N, Skeel R. Ancrod infusion for anticoagulation during and after PTCA in a patient with heparin-induced thrombocytopenia. Cathet Cardiovasc Diagn 1994;32:286-287.
13. Pothoulakis AJ, Neerukonda SK, Ansel G, Jantz RD. Ancrod for coronary angioplasty. Texas Heart Inst J 1995;22:342-346.
14. Lewis BE, Leya FS, Wallis D, Grassman E. Failure of ancrod in the treatment of heparin-induced arterial thrombosis. Can J Cardiol 1998;10:559-561.
15. Doherty DC, Ortel TL, De Bruijn N, Greenberg CS, Van Trigt P. "Heparin-free" cardiopulmonary bypass: first reported use of heparinoid (Org 10172) to provide anticoagulation for cardiopulmomary bypass. Anesthesiology 1990;73:562-565.
16. Kappa J, Fisher C, Todd B, Stenach N, Bell P, Campbell F, Ellison N, Addonizio VP. Intraoperative management of patients with heparin-induced thrombocytopenia. Ann Thorac Surg 1990;49:714-723.
17. Cannell PK, Herrmann RP, Marshall L. Heparinoid during cardiopulmonary bypass. Aust NZ J Med 1991;21:141.
18. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II - integrelin to minimise platelet aggregation and coronary thrombosis-II. Lancet 1997;349:1422-1428.
19. Tcheng JE. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am J Cardiol 1996;78(suppl 3A):35-40.
20. Wilde MI, Markham A. Danaparoid: a Review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. Drugs 1997;54:903-924.
21. Warkentin TE. Danaparoid (ORGARAN) for the treatment of heparin-induced thrombocytopenia and thrombosis: effects on in-vivo thrombin and cross-linked fibrin generation and evaluation of the clinical significance of in-vitro cross-reactivity of danaparoid for HIT-IgG. Blood 1996;88:626A.